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Background: Signal peptide peptidase (SPP), a member of the presenilin-like intra-membrane cleaving aspartyl
protease family, migrates on Blue Native (BN) gels as 100 kDa, 200 kDa and 450 kDa species. SPP has recently been
implicated in other non-proteolytic functions such as retro-translocation of MHC Class I molecules and binding of
misfolded proteins in the endoplasmic reticulum (ER). These high molecular weight SPP complexes might contain
additional proteins that regulate the proteolytic activity of SPP or support its non-catalytic functions.
Results: In this study, an unbiased iTRAQ-labeling mass spectrometry approach was used to identify SPP-interacting
proteins. We found that vigilin, a ubiquitous multi-KH domain containing cytoplasmic protein involved in RNA
binding and protein translation control, selectively enriched with SPP. Vigilin interacted with SPP and both proteins
co-localized in restricted intracellular domains near the ER, biochemically co-fractionated and were part of the same
450 kDa complex on BN gels. However, vigilin does not alter the protease activity of SPP, suggesting that the
SPP-vigilin interaction might be involved in the non-proteolytic functions of SPP.
Conclusions: We have identified and validated vigilin as a novel interacting partner of SPP that could play an
important role in the non-proteolytic functions of SPP. This data adds further weight to the idea that
intramembrane-cleaving aspartyl proteases, such as presenilin and SPPs, could have other functions besides the
proteolysis of short membrane stubs.
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Signal peptide peptidase (SPP) [1] is a member of the
intramembrane cleaving aspartyl protease family that
also includes the presenilins and SPP-like proteases.
Members of this family share characteristic YD, GxGD
and PAL motifs [2]. However, the presenilins cleave Type
I transmembrane proteins [3], while the SPP-like pro-
teases cleave Type II transmembrane proteins [1].
Amongst the SPP-like proteases, the ER-resident SPP is
thought to cleave the membrane-bound stubs of some
secreted proteins following proteolysis of the signal pep-
tide by the signal peptidase [1,4], and in doing so* Correspondence: phs22@cam.ac.uk
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reproduction in any medium, provided the orpresumably releases the stubs from the ER membrane.
SPP may also have additional activities in protein control
in the ER. For example, SPP is required for the disloca-
tion or retro-translocation of MHC Class I molecules in
the presence of the human cytomegalovirus (hCMV)
US2 protein [5]. Others have reported that both catalyt-
ically inactive and wild-type SPP may bind and stabilize
misfolded membrane proteins [6,7].
Preliminary biochemical and biophysical studies by this
and other groups [7] have revealed that the SPP-like pro-
teases in general, and SPP in particular, exist in cell
lysates as higher molecular mass species than would be
predicted from the calculated molecular weight of their
respective monomeric polypeptides (Figure 1). One po-
tential explanation for this observation is that the SPP
proteins might exist as dimers [8,9] or higher order as-
semblies. However, this observation also raises the possi-
bility that there may be ancillary proteins which,
although not required for SPP proteolytic activity, mayThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
188
98
62
49
38
28
kDa Probed  with  Anti-SPP-CT
BN-PAGE
kDa
SPP dimer
SPP monomer
SD
S
PA
G
E
HEK293 
lysate
-
Figure 1 SPP exists in higher molecular weight complexes. Top
panel, HEK293 lysate solubilized in 0.5% DDM and resolved on 16%
Bis-Tris Blue Native-PAGE gels, revealing SPP-containing complexes at
around 450 kDa, 200 kDa and 100 kDa. Lower panel, lysates resolved
on the BN-PAGE were then resolved on the second dimension/SDS-
PAGE. SDS-stable SPP dimer can be found in all three high molecular
weight bands suggesting that the 100 kDa band observed in the
first dimension is a SDS-stable SPP dimer.
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http://www.proteomesci.com/content/10/1/33nevertheless modulate its function. We therefore set out
to determine whether the high molecular weight SPP
complexes might contain other proteins, and if so,
whether these other proteins modulated the SPP protease
activity function of the SPPs. Using an unbiased mass
spectrometry (MS) based approach, vigilin was identifiedFigure 2 Purification of SPP containing complexes. (A) Schematic show
spectrometry analysis of the SPP interacting proteins. (B) Purifications were
panel), demonstrating that the control purification protocol prevented SPP
presence of several co-purified proteins that may represent novel SPP interas a candidate SPP interacting protein. Reciprocal co-
immunoprecipitations confirmed the interaction between
SPP and vigilin. Additionally, SPP and vigilin co-localized
in restricted cellular domains, co-fractionated biochem-
ically and co-migrated as a single band on BN gels.
Results
Isolation of endogenous SPP complexes
SPP and its potential interacting partners were isolated
from native HEK293 cells using a single-step affinity
purification protocol (for a schematic of the protocol
see Figure 2A). Specifically, microsomal membrane iso-
lates were solubilized in 0.5% N-Dodecyl-β-D-maltoside
(DDM) and subjected to anti-SPP affinity purification
using anti-SPP-CT antibody, which recognizes the C-
terminal amino acids 358–377 of SPP. In order to gen-
erate the negative control with which to identify and
exclude non-specific binders, the capture antibody was
pre-blocked with cognate peptide in the control purifi-
cation, and the cognate peptide was further included
during the subsequent affinity matrix washing step.
The purified SPP proteins were resolved by SDS-PAGE
and visualized by Western blotting and silver staining
(Figure 2B). In eluates obtained following SPP-specific
capture, SPP-immunoreactive bands were observed at
42 kDa for monomeric SPP (predicted to be 47 kDa)
and at 70 kDa, interpreted to be SDS-stable dimers.
The discrepancy between the actual molecular weighting the protocol for the purification and iTRAQ-based mass
analysed and compared by Western blot with anti-SPP antibody (left
from being purified, and silver staining (right panel), showing the
acting proteins.
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http://www.proteomesci.com/content/10/1/33and the observed molecular weight on SDS-PAGE is a
common observation, in particular for membrane pro-
teins, and in part reflects the effect of bound detergent
[10]. However, in the control purification, no SPP signal
was observed, demonstrating that the cognate peptide
was able to block the isolation of SPP. Parenthetically,
this method was used because it was much more effective
at reducing SPP binding in the control purification than
siRNA knockdown of SPP (data not shown). The identity
of the co-purified proteins and their level of enrichment
in the cognate-peptide-blocked control equipment were
then determined by iTRAQ-labelling coupled with mass
spectrometry (Figure 3A).
iTRAQ-based analysis of the interactome of SPP
Inspection of the iTRAQ data revealed a robust enrich-
ment of SPP (HM13) (for a list of proteins identified and
their iTRAQ 117:116 ratios, see Table 1 and Additional    1-100
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Figure 3 Representative CID spectra documenting specific co-enrichm
Parallel co-purification with pre-saturated or naive anti-SPP antibody was fo
labeling reactions were setup with the iTRAQ116 label as the negative con
purification. (A) CID spectrum assigned to tryptic peptide AQFEGIVTDLIR wh
peak ratios documented that this peptide was contributed equally by nega
assigned to vigilin-derived peptide EQLAQAVAR which exhibited a strongly
contributed by the specific sample. Graphs on the side depict expanded vi
the iTRAQ signature mass peaks. (C) Human vigilin amino acid sequence (G
and the 14 KH domains are underlined.file 1), while non-specific binders such as the frequently
encountered protein HSP70, had iTRAQ 117:116 ratios
for the signature mass peaks of less than 1.5 (Figure 3A).
However, selective co-enrichment (117:116 ratios ≥ 1.5)
of the ubiquitous 140 kDa RNA-binding protein vigilin
was observed together with SPP (Figure 3B). Thirteen
unique peptides were identified from vigilin in total
(Figure 3C).
Vigilin physically interacts with SPP
To validate the iTRAQ results, reciprocal co-immuno-
precipitation experiments from HEK293 cells were
undertaken. As expected, endogenous vigilin was cap-
tured when using endogenous SPP as the bait protein
(Figure 4A). The reciprocal co-immunoprecipitation
experiments using anti-vigilin antibody was inconclusive
because the SPP bands migrated very closely to the dena-
tured IgG, making it difficult to differentiate SPP bands     Vigilin Protein Sequence 
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                                                                        KH domain 1 
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                                                                     KH domain 12 
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                                    KH domain 14 
8 VVDSEALQVYMKPPAHEEAKAPSRGFVVRDAPWTASSSEKAPDMSSSEEFPSFGAQVAPKTLPWGPKR
ent of vigilin with SPP and non-specific co-purification of HSP70.
llowed by iTRAQ-based quantitation and ESI-MS/MS analyses. iTRAQ
trol, and iTRAQ117 label as peptides derived from the SPP-specific
ich contributed to the identification of HSP70. iTRAQ signature mass
tive control and specific IP eluates. (B) Representative CID spectrum
skewed iTRAQ ratio, demonstrating that this peptide was primarily
ews of the isotopic envelope of the respective precursor masses and
enBank: NP_005327.1) with peptides identified by MS/MS are in red
Table 1 List of proteins identified in the iTRAQ mass spectrometry analysis of SPP interacting proteins
Protein Name Accession Number Symbol Unique Peptides Coverage (%) iTRAQ Ratio (117:116)
Signal peptide peptidase IPI:IPI00152441.3 SPP 6 22.0 331.3
Vigilin IPI:IPI00022228.1 VIGLN 13 14.6 4.3
10 kDa heat shock protein,
mitochondrial
IPI:IPI00220362.4 HSPE1 9 72.3 1.4
Microfibrillar-associated protein 1 IPI:IPI00022790.1 MFAP1 5 20.3 1.3
Heat shock protein 60 IPI:IPI00472102.3 HSP60 23 63.8 1.2
Calnexin precursor IPI:IPI00020984.1 CNX 9 15.5 1.1
Alpha-enolase IPI:IPI00465248.4 ENO1 14 37.2 1.1
Glyceraldehyde-3-phosphate
dehydrogenase
IPI:IPI00219018.6 GAPDH 8 33.5 1.1
Protein C14orf166 IPI:IPI00006980.1 C14orf166 7 39.8 1.1
Stress-70 protein, mitochondrial
precursor
IPI:IPI00007765.5 HSPA9 43 71.4 1.0
Eukaryotic translation initiation
factor 4 gamma 1
IPI:IPI00552639.2 EIF4G1 8 13.6 1.0
ATP synthase O subunit,
mitochondrial precursor
IPI:IPI00007611.1 ATP5O 10 59.1 1.0
Actin, cytoplasmic 1 IPI:IPI00021439.1 ACTB 9 47.5 1.0
130 kDa leucine-rich protein IPI:IPI00329745.4 LPPRC 11 12.8 1.0
Sideroflexin-1 IPI:IPI00009368.3 SFXN1 8 31.8 0.9
ATP-dependent DNA helicase
2 subunit 1
IPI:IPI00644712.3 Ku70 11 20.7 0.9
Prohibitin IPI:IPI00017334.1 PHB 8 34.2 0.9
Heat shock 70 kDa protein 1 IPI:IPI00643932.1 HSP70-1 29 49.3 0.9
Splice Isoform 2 of Nucleophosmin IPI:IPI00220740.1 NPM1 8 41.5 0.9
Protein disulfide-isomerase IPI:IPI00010796.1 PDIA3 24 30.7 0.9
ATP synthase beta chain,
mitochondrial precursor
IPI:IPI00303476.1 ATP5B 9 29.7 0.9
14-3-3 protein zeta/delta IPI:IPI00021263.3 YWHAZ 7 45.3 0.9
NADH-ubiquinone oxidoreductase
24 kDa subunit,
mitochondrial precursor
IPI:IPI00646556.1 NDUFV2 7 38.5 0.9
Heat shock 70 kDa protein 5 IPI:IPI00003362.2 HSPA5 26 52.1 0.9
ATP-dependent RNA helicase A IPI:IPI00215638.5 DHX9 12 16.4 0.8
Splice Isoform 1 of Heat shock
cognate 71 kDa protein
IPI:IPI00003865.1 HSPA8 16 51.4 0.8
ATP-dependent RNA helicase DDX3X IPI:IPI00215637.4 DDX3X 8 15.9 0.8
Vimentin IPI:IPI00646867.1 VIM 12 28.1 0.8
Splice Isoform A1-A of Heterogeneous
nuclear ribonucleoprotein A1
IPI:IPI00465365.3 HNRNPA1 12 64.6 0.8
protein kinase C substrate 80K-H isoform 1 IPI:IPI00419384.1 PRKCSH 11 23.7 0.8
Programmed cell death 8 IPI:IPI00157908.3 PDCD8 7 14.6 0.8
peroxiredoxin 3 isoform b IPI:IPI00374151.1 PRDX3 8 34.0 0.8
FK506-binding protein 10 IPI:IPI00303300.3 FKBP10 8 21.6 0.8
Elongation factor 2 IPI:IPI00186290.5 EEF2 12 20.3 0.8
Reticulocalbin-1 IPI:IPI00015842.1 RCN1 6 19.6 0.8
Splice Isoform 1 of Apoptosis inhibitor 5 IPI:IPI00555572.1 API5 9 24.7 0.8
Citrate synthase, mitochondrial precursor IPI:IPI00025366.4 CS 8 19.3 0.8
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Table 1 List of proteins identified in the iTRAQ mass spectrometry analysis of SPP interacting proteins (Continued)
Transitional endoplasmic reticulum ATPase IPI:IPI00478540.2 VCP 8 13.9 0.8
Single-stranded DNA-binding protein,
mitochondrial precursor
IPI:IPI00029744.1 SSBP1 10 74.3 0.8
Fructose-bisphosphate aldolase A IPI:IPI00465439.4 ALDOA 6 26.7 0.8
Creatine kinase B-type IPI:IPI00022977.1 CKB 6 23.1 0.8
Neutral alpha-glucosidase AB precursor IPI:IPI00472068.1 GANAB 8 16.0 0.8
14-3-3 protein epsilon IPI:IPI00000816.1 YWHAE 9 51.4 0.7
Nuclease sensitive element-binding protein 1 IPI:IPI00031812.2 NSEP1 7 48.6 0.7
Spliceosome RNA helicase BAT1 IPI:IPI00328343.7 DDX39B 9 22.2 0.7
Nucleolin IPI:IPI00743912.1 NCL 16 31.9 0.7
ADP/ATP translocase 2 IPI:IPI00007188.4 SLC25A5 9 35.4 0.7
Prohibitin-2 IPI:IPI00027252.6 PHB2 8 43.8 0.7
ADP/ATP translocase 3 IPI:IPI00291467.6 SLC25A6 9 35.4 0.7
Splice Isoform 2 of Heterogeneous
nuclear ribonucleoprotein K
IPI:IPI00216746.1 HNRPK 12 41.8 0.7
peptidylprolyl isomerase B IPI:IPI00646304.3 PPIB 7 40.7 0.7
Peroxiredoxin-1 IPI:IPI00000874.1 PRDX1 6 34.7 0.7
Mitochondrial precursor proteins
import receptor
IPI:IPI00015602.1 TOMM70A 11 26.2 0.7
Splice Isoform 1 of
Polyadenylate-binding protein 1
IPI:IPI00008524.1 PABPC1 14 29.2 0.7
Splice Isoform 3 of DNA-binding
protein A
IPI:IPI00219148.2 CSDA 6 31.3 0.7
Splice Isoform 3 of Interleukin
enhancer-binding factor 3
IPI:IPI00414335.1 ILF3 9 16.2 0.7
Splice Isoform 2 of Probable
ATP-dependent RNA helicase DDX17
IPI:IPI00651677.1 DDX17 7 19.9 0.7
40S ribosomal protein S10 IPI:IPI00008438.1 RPS10 7 49.1 0.7
Elongation factor 1-alpha 1 IPI:IPI00472724.1 EEF1A1 8 22.5 0.7
Endoplasmin IPI:IPI00027230.3 HSP90B1 23 32.7 0.7
Dihydrolipoyllysine-residue succinyltransferase
component of 2- oxoglutarate dehydrogenase
complex, mitochondrial precursor
IPI:IPI00420108.4 DLSTP1 9 31.8 0.7
Splice Isoform B1 of Heterogeneous nuclear
ribonucleoproteins A2/B1
IPI:IPI00396378.3 HNRNPA2B1 19 57.5 0.7
Splice Isoform Long of Splicing factor,
proline- and glutamine-rich
IPI:IPI00010740.1 SFPQ 26 50.2 0.7
CKAP4 protein (Fragment) IPI:IPI00433214.1 CKAP4 16 34.3 0.6
Calreticulin IPI:IPI00020599.1 CALR 6 25.2 0.6
Protein disulfide-isomerase A6 IPI:IPI00644989.1 PDIA6 9 27.7 0.6
ATP synthase alpha chain,
mitochondrial precursor
IPI:IPI00440493.2 ATP5A1 15 36.7 0.6
Nucleobindin-2 IPI:IPI00009123.1 NUCB2 5 23.6 0.6
40S ribosomal protein SA IPI:IPI00553164.3 RPSA 7 39.1 0.6
Splice Isoform C1 of Heterogeneous nuclear
ribonucleoproteins C1/C2
IPI:IPI00216592.1 HNRNPC 12 52.9 0.6
Heterogeneous nuclear ribonucleoprotein G IPI:IPI00304692.1 RBMX 16 49.1 0.6
Serine hydroxymethyltransferase,
mitochondrial precursor
IPI:IPI00002520.1 SHMT2 7 17.9 0.6
Protein disulfide-isomerase A4 IPI:IPI00009904.1 PDIA4 15 35.7 0.6
Lu et al. Proteome Science 2012, 10:33 Page 5 of 13
http://www.proteomesci.com/content/10/1/33
Table 1 List of proteins identified in the iTRAQ mass spectrometry analysis of SPP interacting proteins (Continued)
Proliferation-associated protein 2G4 IPI:IPI00299000.4 PA2G4 14 36.6 0.5
Non-POU domain-containing
octamer-binding protein
IPI:IPI00304596.3 NONO 18 42.0 0.5
Histone H1.2 IPI:IPI00217465.4 HIST1H1C 5 34.0 0.5
Complement component 1,
Q subcomponent-binding protein,
mitochondrial precursor
IPI:IPI00014230.1 C1QBP 6 42.9 0.5
THO complex subunit 4 IPI:IPI00328840.7 THOC4 7 37.1 0.4
Vigilin or SPP-derived peptides were selectively enriched in the SPP purification sample compared to the control purification, while all other proteins identified had
iTRAQ 117:116 ratios of less than 1.5.
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http://www.proteomesci.com/content/10/1/33from non-specific IgG bands. In order to detect vigilin
interacting with SPP after vigilin immunoprecipitation,
we generated a HEK293 cell line that stably expressed
FLAG-tagged vigilin. Expression pattern of FLAG-tagged
vigilin in this cell line was similar to the expression pat-
tern of the endogenous vigilin (compare Figure 5A and
Figure 5B), and allowed the use of mouse anti-FLAG
antibody, instead of the rabbit anti-vigilin antibody. Simi-
lar to the endogenous SPP co-immunoprecipitation
experiments, the capture with anti-SPP antibody was
able to specifically co-immunoprecipitate vigilin-FLAG
and SPP while no bands were observed from control co-
immunoprecipitations with pre-immune rabbit serum
(Figure 4B). Also, this interaction is a specific because
SPPL2b did not co-immunoprecipitates with vigilin, but
additional SPP-like proteases will need to be tested to
determine the extent of this specificity (Figure 4B). Co-A
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Figure 4 SPP interacts with vigilin. (A) Co-immunoprecipitation with ant
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blot was probed with anti-FLAG antibody. (C) Co-immunoprecipitation with
the FLAG-tagged vigilin expressing HEK293 cell line. The blot was probed w
three independent experiments.immunoprecipitation experiments using anti-FLAG anti-
body (Figure 4C) captured vigilin-FLAG as well as its
interacting partner SPP. Interestingly, the FLAG IP cap-
tured predominantly dimers and trimers of SPP but not
monomers.
Vigilin can be found in the ER fraction and co-localizes
with SPP
To further explore the possibility of an in vivo vigilin-
SPP interaction, subcellular iodixanol gradient fraction-
ation studies were performed. In agreement with prior
data showing that SPP was ER resident [11-13], SPP was
found in fractions containing the ER marker calnexin,
but was absent from the cytoplasmic and Golgi fractions
(Figure 5A). Vigilin, as expected, was predominantly
found in the cytoplasmic fractions. However, in agree-
ment with this prior data, a small proportion of188
98
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kDa
SPP trimer
SPP dimer
SPP monomer
Probed with Anti-SPP-CT
SDS-PAGE
C
i-SPP-CT antibody pulled down endogenous vigilin. The blot was
band. (B) In a HEK293 cell line stably expressing FLAG-tagged vigilin,
, while antibody against SPPL2b did not pull down vigilin-Flag. The
anti-FLAG antibody pulled-down SDS-stable SPP dimers and trimers in
ith anti-SPP-CT antibody. Data shown are representative blots from
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Figure 5 Vigilin is found in ER fraction. (A) HEK293 cells were homogenized and fractionated on an iodixanol gradient. Fractions were
collected drop-wise and probed for vigilin, ER-resident SPP, ER-marker calnexin and Golgi apparatus-marker GM130. Vigilin was primarily found in
the later (upper) fractions but a small proportion was present in the fractions 3 and 4, which also contained the peak fractions of SPP and
calnexin. (B) HEK293 stably expressing vigilin-FLAG were homogenized and fractionated on an iodixanol gradient. Fractions were collected
drop-wise and probed for vigilin (using anti-FLAG antibody), SPP, calnexin and GM130. Identical to the endogenous vigilin and SPP distribution,
the FLAG-tagged vigilin was found mainly in the cytoplasmic fractions but also found in fraction 4, which also contained the peak fractions of SPP
and calnexin.
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http://www.proteomesci.com/content/10/1/33endogenous vigilin also co-fractionated in the ER mem-
brane fractions along with SPP and calnexin. The frac-
tions containing peak levels of the ER-bound vigilin also
corresponded to the fractions containing the peak levels
of SPP and calnexin. This result was not due to ‘leakage’
between the fractions or mixing during the collection ofthe fractions because there was a gap of 2–3 fractions
where vigilin was not present in the collected fractions.
Identical results were obtained for the FLAG-tagged vigi-
lin cell line, thereby indicating that the expression of the
FLAG-tagged vigilin had not caused it to be mis-
localized (Figure 5B).
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http://www.proteomesci.com/content/10/1/33To corroborate this biochemical evidence for an inter-
action, immunofluorescence studies in the HEK293 cells
were performed in order to query whether co-
localization of SPP and vigilin can be documented. Im-
munofluorescence studies were not possible with native
cells expressing endogenous vigilin because the anti-
bodies against SPP and vigilin were both raised in rab-
bits. Moreover, while the available anti-vigilin antibodies
detect authentic vigilin-immunoreactive bands on West-
ern blots, they also detect a few other weak non-specific
bands. This raised the concern that the immunofluores-
cence studies could be misled by these non-specific epi-
topes. Consequently, we investigated the localisation of
FLAG-tagged vigilin. As noted above, this strategy was
safe because the biochemical fractionations studies
demonstrated that neither the presence FLAG-tag nor
the over-expression of the FLAG-tagged vigilin caused
changes in the localisation of vigilin. In HEK293 cells
expressing FLAG-tagged vigilin, the majority of the vigi-
lin signal (green signal in Figure 6) was present in the
cytoplasm, whereas the SPP signal (red signal in Figure 6)
was in the ER. Nevertheless, a small proportion of SPP
and vigilin showed co-localization as discrete small
round foci on ER structures (yellow dots highlighted
with white arrows in Figure 6). This association of vigilin
with ER membranes has been previously documented
[11-13].
Vigilin is part of the 450 kDa SPP complex
To determine whether vigilin was a component of any of
the three SPP high molecular weight SPP complexes
(450 kDa, 200 kDa and 100 kDa; Figure 1), cell lysatesFigure 6 Vigilin co-localizes with SPP. HEK293 expressing vigilin-FLAG w
channel) antibodies, counter-stained with DAPI for the nuclei. Lower panel,
proportion of vigilin co-localizes with SPP in vitro (examples of co-localizatio
bar represents 10 μm.were resolved on BN-PAGE and probed for vigilin and
SPP (Figure 7). These studies revealed that vigilin specif-
ically co-migrates with the 450 kDa band of SPP with
both native HEK293 and vigilin-FLAG lysates. Of note,
the observed co-migration of SPP and vigilin in this ana-
lysis was not due to a non-specific compression of pro-
tein bands that can sometimes be observed on the BN
gels (and appeared to account in this analysis for the 700
kDa band in the Coomassie-stained HEK293 lysates)
(Figure 7A). Furthermore, because vigilin co-migrated
only with the 450 kDa, and not with the more abundant
200 kDa and 100 kDa SPP complexes, this result argued
against an artifactual interaction between vigilin and
SPP. Indeed, it demonstrates that vigilin is a specific
component of the high molecular weight SPP complex.
Vigilin does not affect the aspartyl protease activity of
SPP
To determine if vigilin affects the proteolytic activity of
SPP, we performed an in vitro SPP activity assay using a
peptide substrate derived from the signal peptide of pro-
lactin [14]. The SPP activity of lysates from mock-
transfected HEK293 cells and cells transfected with
vigilin-specific siRNAs or vigilin-FLAG expression plas-
mids were compared (Figure 8). No significant changes
in the band intensities of the expected prolactin sub-
strate cleavage products were observed.
Discussion
Signal peptide peptidase (SPP), which exists as a compo-
nent of several different high molecular weight
membrane-bound protein complexes, has importantere immunostained with SPP-CT (red channel) and FLAG (green
magnified view of cell in white box from the top panel. Only a small
n are indicated by white arrows in the magnified images). The white
A
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4
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98
38
98
62
49
38
kDa SDS PAGE
Vigilin
GAPDH
SPP monomer
SPP dimer
Substrate
Product
B
Figure 8 Vigilin expression level does not alter the protease activity of SPP. (A) The knockdown and over-expression of vigilin did not
substantially alter the ability of SPP to cleave the prolactin substrate in the in vitro SPP assay. The positive control used in this study is a purified
yeast homolog of SPP that cleaves the prolactin signal peptide substrate, while the negative control is set up without the addition of proteins.
Expression level of vigilin was compared to the loading control, GAPDH. Total lysate concentration was adjusted to ensure equal loading of
protein samples into the reaction. Data shown are representative blots from three independent experiments. (B) Densitometry analysis of three
independent knockdown/overexpression and reactions. Bars represent mean± s.e.m. The unpaired t-test was performed using Prism (n.s., not
significant, p-value > 0.05).
BA
Figure 7 Vigilin is part of the 450 kDa SPP complex. (A) HEK293 cell lysate were solubilized in 0.5% DDM and resolved on 4-16% BN-PAGE
gels. As shown on the left panel, SPP formed three distinct complexes at 450 kDa, 200 kDa and 100 kDa. Lysates probed with anti-vigilin antibody
reveals that endogenous vigilin only forms one distinct complex on the BN-PAGE and that band co-migrates with the 450 kDa SPP complex.
Lysates were also Coomassie stained to show that the 450 kDa SPP and vigilin containing complex was not a compression artifact of BN-PAGE
gels, such as the band migrating at 700 kDa. (B) HEK293 vigilin-FLAG cell lysate were solubilized in 0.5% DDM and resolved on 4-16% BN-PAGE
gels reveal that vigilin-FLAG also co-migrates with the 450 kDa SPP complex only. Data shown are representative blots from three independent
experiments.
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latter functions, which are not well-characterized, may
relate to protein quality control.
The biochemical and cellular data presented here sug-
gest that the SPP-vigilin interaction is genuine and highly
selective, although it is also clear that only a minor pro-
portion of both proteins are involved in this interaction.
Despite this seemingly minor interaction, vigilin mole-
cules interact with SPP with high affinity on the basis
that despite a high concentration of DDM in the
solubilization step, the interaction between SPP and vigi-
lin was still preserved. This interaction is also highly se-
lective for SPP in high molecular weight complexes, both
in immunoprecipitation and BN-PAGE experiments.
There is considerable uncertainty about whether mono-
meric, dimeric or higher-order oligomers of SPP are
catalytically active [7-9,14]. However, some evidence sug-
gests that the higher-order species may not be catalytic-
ally active. If correct, as discussed below, this would
suggest that the interaction of vigilin with these higher-
order oligomers of SPP may relate to a non-proteolytic
SPP activity.
A possible function of vigilin is to modulate the activ-
ity of SPP. Indeed, one obvious hypothesis is that vigilin
might affect the proteolytic activity of SPP in a manner
analogous to the selective modulating effect of TMP21
[15] and gSAP [16] on presenilin complex–mediated γ-
secretase activity. However, unexpectedly, we found that
neither vigilin knockdown nor overexpression had any
effect on the proteolytic activity of SPP. It is also possible
that SPP may modulate the biological activity of vigilin,
although this could not be tested as no vigilin-specific
biochemical assay exists.
An alternative effect of the SPP-vigilin interaction is
that vigilin could modulate the putative functions of SPP
in protein quality control in the ER. Testing this hypoth-
esis will require much further work, and is beyond the
focus of the current paper. However, vigilin has previ-
ously been shown to bind RNA, presumably via its KH
domains [17-19], and can be localized with free and
membrane-bound ribosomes [11-13]. The binding of
mRNA by vigilin may stabilize the mRNA molecules and
could be required for the localization of mRNA to ac-
tively translating ribosomes [11,20-22]. This observation,
together with SPP’s putative function in binding mis-
folded protein, suggests that the vigilin-SPP complex
could potentially be involved in the translation and qual-
ity control of membrane proteins. For instance, the
vigilin-SPP interaction could ensure that SPP is near to
the site of newly synthesized polypeptides destined for
insertion into the ER membrane. If so, this might allow
the vigilin-SPP complex to be involved in the regulation
of translation and the binding/removal of newly-made
misfolded membrane proteins. The latter might beachieved by a combination of: 1) dislocation/transloca-
tion back across the ER membrane (as shown for SPP’s
role with MHC Class I molecules [5]); and 2) proteolytic
cleavage of fragments in the membrane itself.
Conclusions
Using an unbiased iTRAQ mass spectrometry-based ap-
proach, we have identified the multi-KH domain protein
vigilin as a potential interacting protein of SPP among the
78 proteins identified. We have confirmed the interaction
between SPP and vigilin using a series of experiments that
included co-immunoprecipitations, subcellular fraction-
ation, native gel and co-localization studies. Vigilin does
not appear to modulate the protease activity of SPP but
instead vigilin-SPP complex could have a role in mem-
brane protein quality control in the ER.
Methods
Antibodies and resins
The following antibodies were used in this study: rabbit
anti-SPP C-terminus polyclonal antibody (SPP-CT,
Abcam, Cambridge, UK), rabbit anti-SPP N-terminus
polyclonal antibody (SPP-NT, Abcam), rabbit anti-vigilin
polyclonal antibody (Abcam), rabbit anti-SPPL2b poly-
clonal antibody (Abcam) mouse anti-FLAG monoclonal
antibody (Clone M2, Sigma-Aldrich, Dorset, UK), rabbit
anti-GM130 polyclonal antibody (Abcam), rabbit anti-
calnexin polyclonal antibody (Abcam) and mouse anti-
myc monoclonal antibody (Invitrogen). The HA-agarose
and FLAG-agarose affinity gels were obtained from
Sigma-Aldrich and Protein G-sepharose was from GE
Healthcare (Little Chalfont, UK).
Molecular cloning
Vigilin cDNA (ORFeome clone number: 100011448) was
amplified by PCR using the forward (sequence: 5’-GGC-
GCCATGAGTTCCGTTGCAGTTTTG-3’) and reverse
(sequence: 5’-GGCCGGTTACTACTTGTCATCGTCAT-
CCTTGTAGTCTCGTTTGGGGC CCCAAGGGAG-3’)
primers and inserted into the TA-cloning site of the
pcDNA3.3 mammalian expression vector (Invitrogen,
Paisley, UK) with a single FLAG tag (N-DYKDDDDK-C)
introduced directly to the C-terminus of the vigilin
cDNA.
Cell culture, transfection and siRNA knockdown
Human Embryonic Kidney 293 (HEK293) cells were cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM,
Sigma-Aldrich) containing 10% fetal bovine serum and
1% penicillin/streptomycin. Following sequence verifica-
tion, the pcDNA3.3-vigilin-FLAG plasmid was trans-
fected into HEK293 cells with FuGene 6 (Roche Applied
Science, Burgess Hill, UK). Stable transfectants were
clonally selected with 1 mg/ml Geneticin G418. Knock-
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pool siRNA (Dharmacon, Epsom, UK), which was trans-
fected into HEK293 cells using the Dharmafect 1 reagent
(Dharmacon) and, subsequently, incubated for 72–96 h.
Membrane preparation and affinity purification of
endogenous SPP
Antibodies were cross-linked to Protein G sepharose
with 0.025 M Borax pH 9.45 in the presence of 20 mM
dimethylpimedilate (Sigma-Aldrich) and residual
uncross-linked antibody was removed with 100 mM gly-
cine HCl pH 3.0. For the preparation of microsomal
membranes, the cell pellet was resuspended and homo-
genized in sucrose lysis buffer (25 mM HEPES pH 7.4, 4
mM EDTA, 0.25 M sucrose, complete protease inhibitor
cocktail (Roche)). Following centrifugation at 2,000 × g
for 10 min, the supernatant was further centrifuged at
100,000 × g (Ti45 rotor, Beckman Coulter, High
Wycombe, UK) for 60 min to isolate microsomal mem-
branes. Membrane lysates were solubilized with 0.5%
(wt/vol) n-dodecyl-β-D-maltoside (DDM, Anatrace) in
HEPES buffer (25 mM HEPES pH 7.4, 150 mM NaCl, 4
mM EDTA, complete protease inhibitor cocktail).
Lysates were pre-cleared with pre-immune serum cross-
linked to protein G sepharose overnight, and SPP was
then purified with SPP-CT antibody cross-linked to pro-
tein G sepharose. Next, the beads were subjected to at
least 5 washes with HEPES buffer containing 0.02% (wt/
vol) DDM and a single high-salt wash step in HEPES
buffer with 300 mM NaCl. SPP and its interacting pro-
teins were eluted by pH drop with Tris–HCl pH 3.0. To
generate a negative control, anti-SPP antibody was pre-
saturated with 100 μg/ml of cognate peptide (sequence:
N-TESKEGTEASASKGLEKKEK-C) and washes with 100
μg/ml of the aforementioned peptide was also included.
Protein reduction, alkylation and trypsinization
Protein-containing fractions were denatured in the pres-
ence of 9 M urea, followed by reduction with 5 mM
tris-(2-carboxyethyl)-phosphine for 30 min at 60°C and
alkylation with 9 mM 4-vinylpyridine for 1 h at room
temperature in the dark. Samples were diluted five-fold
to ensure that the concentration of urea did not ex-
ceed 2 M. Tryptic digestion was initiated by the
addition of 1% (wt/wt) of side chain-modified, TPCK-
treated porcine trypsin and allowed to proceed at 37°C
for 6 h.
iTRAQ labeling and mass spectrometry
The steps for the labeling of peptides with iTRAQ
reagents, two-dimensional separation of peptide mixtures
by offline strong-cation exchange (SCX) and online
reversed phase (RP) liquid chromatography and subse-
quent analysis by electrospray tandem massspectrometry have been described previously [23]. Sam-
ples derived from control and SPP-specific purifications
were iTRAQ-labeled with iTRAQ-116 and iTRAQ-117
reagents, respectively.
Database searches
Collision induced dissociation (CID) spectra were ana-
lyzed using ProteinPilot (Version 2.0, Applied Biosys-
tems, MDS Sciex). The lists of candidate interacting
proteins were subjected to the following filters: (i) all
identifications of proteins had to be based on at least
two CID spectra which passed the 95% confidence score
returned by the ProteinPilot software; (ii) assignments to
non-iTRAQ-labeled peptides or CID spectra with indi-
vidual confidence scores of less than 90% were not
included in the calculation of enrichment ratios based on
iTRAQ signature mass signal intensities. Raw iTRAQ
ratios were corrected for impurity levels of individual re-
agent lots determined by the manufacturer. The mass
tolerance range between expected and observed masses
used for database searches was ±150 ppm for MS peaks,
and ±0.15 Da for MS/MS fragment ions. All samples
were searched against the International Protein Index
(IPI) database disseminated through EMBL/EBI.
Co-immunoprecipitations and western blotting
Homogenized HEK293 cells were solubilized in ice-cold
HEPES buffer with 0.5% DDM for 60 min and centri-
fuged at 100,000 × g for 30 min to remove insoluble ma-
terial. Co-immunoprecipitations were carried out with
500–1000 μg of solubilized total lysate utilizing anti-
bodies against SPP-CT, SPPL2b and FLAG-tag, with pre-
immune rabbit serum and antibody against the HA-tag
serving as the control for the SPP/SPPL2b and FLAG
IPs, respectively. After pre-clearing, lysates were incu-
bated overnight at 4°C with antibody and Protein G
Sepharose or pre-conjugated affinity resins. Resin was
then washed five times with 0.02% DDM in HEPES buf-
fer. The precipitated proteins were eluted with 1 × sam-
ple buffer (LDS, Invitrogen). For immunoblotting, the
samples were resolved on 12% Bis-Tris NuPAGE gels
(Invitrogen), transferred onto polyvinylidene fluoride
membranes (PVDF, Millipore, Watford, UK) and probed
with appropriate primary and secondary antibodies.
Blue native-polyacrylamide gel electrophoresis (BN-PAGE)
Membrane lysates solubilized in 0.5% DDM were
resolved on one-dimensional BN-Page (4-16% Native-
PAGE Bis-Tris gels, Invitrogen), incubated in 1% SDS for
15 min and transferred onto PVDF membranes for
Western Blot analysis. For the second dimension SDS-
PAGE, the lanes from the BN-PAGE were excised and
resolved on SDS-PAGE gels (12% Bis-Tris NuPage gels,
Invitrogen).
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HEK293 cells were homogenized in Tris buffer (25 mM
Tris pH 7.4, 25 mM NaCl, 130 mM KCl, 1 mM EGTA,
complete protease inhibitor cocktail) and centrifuged at
1,000 × g for 10 min then at 3,000 × g for 10 min. The
resulting supernatant was placed on top of a step gradi-
ent consisting of 1 ml layers of 30, 25, 20, 15, 12.5, 10,
7.5, 5, and 2.5% (vol/vol) iodixanol (Sigma-Aldrich) in
Tris buffer. Following centrifugation at 92,000 × g (SW40
rotor, Beckman Coulter) for 30 min, 11 fractions were
collected from the bottom of the centrifuge tube. The
fractions were analyzed for the presence of the SPP, vigi-
lin and protein markers of the subcellular organelles.
Immunofluorescence microscopy
HEK293 cells were plated onto cover-slips pre-coated
with 0.01% (wt/vol) poly-L-lysine solution (Sigma-
Aldrich). HEK293 cells were fixed with 10% (vol/vol) for-
malin, perforated with PBS-T (1 × PBS with 0.1% (vol/
vol) Triton X-100) and blocked with 10% (vol/vol) nor-
mal goat serum (Abcam) in PBS-T. Cells were incubated
for 60 min in anti-SPP and anti-vigilin primary anti-
bodies diluted in 10% normal goat serum and subse-
quently incubated in the appropriate species-specific
Alexa fluorescent dye conjugated secondary antibodies
(Invitrogen) for 30 min. The immunostained cells were
viewed by confocal microscopy (LSM510 META, Carl
Zeiss, Welwyn Garden City, UK).
In vitro SPP activity assay
The proteolytic activity of SPP was determined using an
in vitro assay with myc and FLAG double tagged peptide
derived from the signal peptide of prolactin [14] as the
substrate. Briefly, the final SPP assay mixture (40 mM
HEPES pH 7.0, 200 mM sucrose, 4 mM EDTA, 0.5 μM
substrate, 10 mM β-mercaptoethanol, 0.2% (wt/vol) polar
lipids extracted from Escherichia coli (Avanti, Alabaster,
AL, USA), complete protease inhibitor cocktail and cel-
lular lysates) was incubated on ice for 30 min to allow
substrate binding and the reaction was carried out at 30°
C for 2–4 h. The reaction was stopped by the addition of
sample loading buffer. Substrate and product bands were
separated on 16% Tricine gels (Invitrogen) and probed
with anti-myc antibody. Reaction product and GAPDH
band intensities were estimated using the ImageJ soft-
ware package (version 1.45l, US National Institutes of
Health, Bethesda, MD, USA) and the unpaired t-test was
performed using the Prism statistical software package
(version 5, GraphPad, La Jolla, CA, USA).
Additional file
Additional file 1: Complete list of peptides identified in the iTRAQ
mass spectrometry analysis of SPP interacting proteins. Vigilin orSPP-derived peptides were selectively enriched in the SPP purification
sample compared to the control purification, while all other proteins
identified had iTRAQ 117:116 ratios of less than 1.5.
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